Clinical Trial Update: Tolvaptan to Reduce Length of Stay in Hospitalized Patients With Cirrhosis and Hyponatremia [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating whether tolvaptan reduces hospital length of stay in patients with cirrhosis and hyponatremia. The study was terminated and results wer…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cirrhosis
• Hyponatremia

Drugs mentioned

• tolvaptan (tolvaptan)

Snippet

Sponsor: NYU Langone Health | Conditions: Hyponatremia | Phase 4 | Status: TERMINATED | Results posted: 2016-04-11